Skip to main content

Market Overview

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences


MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:

  • The Piper Sandler 32nd Virtual Annual Healthcare Conference.
  • The Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 4:20 p.m. Eastern Time.

A replay of the pre-recorded Piper Sandler fireside chat is currently available in the News & Events section of Milestone's website at, and a live webcast of the Evercore fireside chat can be accessed in the same section of Milestone's website. An archived replay of the webcasts will be available on the same website for approximately 90 days following the presentations.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit and follow the Company on Twitter at @MilestonePharma. 


David Pitts
Argot Partners

(PRNewsfoto/Milestone Pharmaceuticals)


Cision View original content to download multimedia:

SOURCE Milestone Pharmaceuticals, Inc.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at